Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in Wegovy.

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Golden Globes host Nikki Glaser shared why she supports people using the injectable drug Ozempic for weight loss, and also ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...